These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 18957679)

  • 1. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
    Di Maio M; Daniele B; Gallo C; Perrone F
    J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
    [No Abstract]   [Full Text] [Related]  

  • 2. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial design in hepatocellular carcinoma.
    Johnson PJ; Billingham LJ
    Best Pract Res Clin Gastroenterol; 2005 Feb; 19(1):119-27. PubMed ID: 15757808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 25-year review of sequential methodology in clinical studies.
    Todd S
    Stat Med; 2007 Jan; 26(2):237-52. PubMed ID: 17139691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials.
    Farrington P; Miller E
    Methods Mol Med; 2003; 87():335-52. PubMed ID: 12958466
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 7. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 11. A strategic framework for novel drug development in multiple myeloma.
    Anderson KC; Hannah AL; Pazdur R; Farrell AT
    Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022
    [No Abstract]   [Full Text] [Related]  

  • 12. Critical issues in the design and implementation of clinical trials in hepatocellular carcinoma.
    Johnson PJ
    Expert Rev Anticancer Ther; 2003 Aug; 3(4):421-3. PubMed ID: 12934653
    [No Abstract]   [Full Text] [Related]  

  • 13. Statistics in clinical trials.
    Green SJ; Pauler DK
    Curr Oncol Rep; 2004 Jan; 6(1):36-41. PubMed ID: 14664759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary on 'designing phase II studies in cancer with time-to-event endpoints'.
    Case D; Morgan T
    Clin Trials; 2008; 5(3):222-3; discussion 223-4. PubMed ID: 18559410
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical studies--what is the putting of the question?].
    Guttenberger R
    Strahlenther Onkol; 1999 Apr; 175 Suppl 1():14-6. PubMed ID: 10230452
    [No Abstract]   [Full Text] [Related]  

  • 16. "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials.
    Penel N; Clisant S; Lefebvre JL; Adenis A
    J Clin Oncol; 2009 Sep; 27(26):e105. PubMed ID: 19667257
    [No Abstract]   [Full Text] [Related]  

  • 17. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 18. Curtailed two-stage designs with two dependent binary endpoints.
    Chen CM; Chi Y
    Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma: the need for progress.
    Thomas MB; Zhu AX
    J Clin Oncol; 2005 May; 23(13):2892-9. PubMed ID: 15860847
    [No Abstract]   [Full Text] [Related]  

  • 20. An overview of clinical trials.
    Rich K
    J Vasc Nurs; 2004 Mar; 22(1):32-4. PubMed ID: 14981501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 35.